KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With ...
KEYTRUDA plus LENVIMA with TACE reduced disease progression risk by 34% in Phase 3 LEAP-012 trial for unresectable, non-metastatic HCC, with PFS of 14.6 months vs. 10.0 months for TACE alone. OS showed a trend toward improvement but was not statistically significant.
Reference News
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With ...
KEYTRUDA plus LENVIMA with TACE reduced disease progression risk by 34% in Phase 3 LEAP-012 trial for unresectable, non-metastatic HCC, with PFS of 14.6 months vs. 10.0 months for TACE alone. OS showed a trend toward improvement but was not statistically significant.